Curia, a leading contract development and manufacturing organisation (CDMO), announced the approval of three additional active pharmaceutical ingredients (APIs) in China: Loteprednol Etabonate, Bromocriptine, and Betamethasone-21-Phosphate Disodium Salt. These approvals further expand Curia’s growing portfolio in one of the world’s largest pharmaceutical markets and reinforce its commitment to helping customers navigate complex global regulatory pathways.

The milestone builds on Curia’s established track record in China, where the company has successfully registered more than 20 APIs and achieved multiple NMPA “A” status approvals. Supported by a dedicated local Regulatory Affairs team and extensive experience managing global regulatory submissions, Curia continues to help customers accelerate market access while meeting the evolving requirements of China’s regulatory framework.